News Releases

Nov 03, 2021
SHANGHAI and GAITHERSBURG, Md. , Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in
Oct 22, 2021
-  I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growing San Diego biotech hub -  The new site will complement I-Mab's   Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US
Displaying 1 - 10 of 59